Millipore Sigma Vibrant Logo

IM78 Anti-MMP-13 (Ab-4) Mouse mAb (VIIIA2)

Anti-MMP-13 (Ab-4) Mouse mAb (VIIIA2) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Collagenase-3, Anti-Matrix Metalloproteinase 13

IM78
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Host
      M
      Description
      Overview

      This product has been discontinued.





      Recognizes the ~54-60 kDa latent and the ~48 kDa active forms of MMP-13 in PMA-treated HT1080 cells and breast, bladder, and ovarian carcinoma tissue.
      Catalogue NumberIM78
      Brand Family Calbiochem®
      SynonymsAnti-Collagenase-3, Anti-Matrix Metalloproteinase 13
      Application Data
      Detection of human MMP-13 by immunohistochemistry. Sample: Human placenta tissue fixed in formalin and embedded in paraffin. Primary antibody: Anti-MMP-13 (Ab-4) Mouse mAb (VIIIA2) (Cat. No. IM78) (1:25). Detection: fluorescence.
      References
      ReferencesShlopov, B., et al. 1997. Arthritis Rheum. 40, 2065.
      Knauper V., et al. 1996. J. Biol. Chem. 271, 1544.
      Freije, J.M.P., et al. 1994. J. Biol. Chem. 269, 16766.
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. In Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 99.
      Product Information
      DeclarationNot available for sale in Japan.
      FormLiquid
      FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
      Positive controlConditioned medium from PMA-treated HT-1080 cells or breast, bladder, or ovarian carcinomas
      Preservative≤0.1% sodium azide
      Applications
      Key Applications Affinity Purification
      Frozen Sections
      Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesAffinity Purification (see comments)
      Frozen Sections (1:50-1:100)
      Immunoblotting (1:200-1:400)
      Paraffin Sections (1:50-1:100, heat/pressure cooker pre-treatment required)
      Application CommentsThis antibody has been reported to work for affinity purification methods. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenrecombinant, human MMP-13
      ImmunogenHuman
      CloneVIIIA2
      HostMouse
      IsotypeIgG₁
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsFor long-term storage, aliquot and freeze (-20°C). Avoid freeze/thaw cycles.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      IM78 0

      Documentation

      Anti-MMP-13 (Ab-4) Mouse mAb (VIIIA2) SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-MMP-13 (Ab-4) Mouse mAb (VIIIA2) Certificates of Analysis

      TitleLot Number
      IM78

      References

      Reference overview
      Shlopov, B., et al. 1997. Arthritis Rheum. 40, 2065.
      Knauper V., et al. 1996. J. Biol. Chem. 271, 1544.
      Freije, J.M.P., et al. 1994. J. Biol. Chem. 269, 16766.
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. In Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 99.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-September-2007 RFH
      SynonymsAnti-Collagenase-3, Anti-Matrix Metalloproteinase 13
      ApplicationAffinity Purification (see comments)
      Frozen Sections (1:50-1:100)
      Immunoblotting (1:200-1:400)
      Paraffin Sections (1:50-1:100, heat/pressure cooker pre-treatment required)
      Application Data
      Detection of human MMP-13 by immunohistochemistry. Sample: Human placenta tissue fixed in formalin and embedded in paraffin. Primary antibody: Anti-MMP-13 (Ab-4) Mouse mAb (VIIIA2) (Cat. No. IM78) (1:25). Detection: fluorescence.
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with p3-X63-Ag8.653 mouse myeloma cells. Recognizes the ~60 kDa latent and the ~48 kDa active forms of MMP-13.
      BackgroundMatrix metalloproteinases (MMPs) are a family of enzymes that are responsible for the degradation of extracellular matrix components such as collagen, laminin and proteoglycans. In addition to sequence homology, all MMPs share the following characteristics: the catalytic mechanism is dependent upon a zinc ion at the active center, they cleave one or more extracellular matrix components, they are secreted as zymogens which are activated by removal of an ~10 kDa segment from the N-terminus and they are inhibited by tissue inhibitor of metalloproteinases (TIMP). These enzymes are involved in normal physiological processes such as embryogenesis and tissue remodeling and may play an important role in angiogenesis, arthritis, periodontitis, and metastasis. Matrix metalloproteinase-13 (MMP-13), also known as collagenase-3, is secreted as a 60 kDa proenzyme which is proteolytically processed to the 48 kDa active MMP-13 form. MMP-13 shows substrate specificity toward interstitial collagens I-III and gelatin, preferentially cleaving type II collagen over types I and III and cleaving fibrillar type I collagen with comparable efficiency to MMP-1 and MMP 8. MMP-13 is expressed in breast carcinomas and may be important in the turnover of articular cartilage, which is rich in type II collagen. Active MMP-13 can be inhibited in vitro by chelators of divalent ions such as EDTA and o-phenanthroline and in vivo by TIMP-1, TIMP-2, and TIMP 3. Numerous studies have shown a correlation between collagenase expression and metastatic potential and suggest that it may be a useful marker for the diagnosis or prognosis of cancer.
      HostMouse
      Immunogen speciesHuman
      Immunogenrecombinant, human MMP-13
      CloneVIIIA2
      IsotypeIgG₁
      Specieshuman, mouse, rabbit
      Positive controlConditioned medium from PMA-treated HT-1080 cells or breast, bladder, or ovarian carcinomas
      FormLiquid
      FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsThis antibody has been reported to work for affinity purification methods. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFor long-term storage, aliquot and freeze (-20°C). Avoid freeze/thaw cycles.
      Toxicity Standard Handling
      ReferencesShlopov, B., et al. 1997. Arthritis Rheum. 40, 2065.
      Knauper V., et al. 1996. J. Biol. Chem. 271, 1544.
      Freije, J.M.P., et al. 1994. J. Biol. Chem. 269, 16766.
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. In Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 99.